ClinicalTrialsFinder

HR Positive/HER2 Low Expression Metastatic Breast Cancer Clinical Trials in Guangzhou, Guangdong

1 recruitingGuangzhou, Guangdong, China

Showing 1–1 of 1 trials

Recruiting
Phase 3

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University288 enrolled3 locationsNCT05904964